Home | K36tx
K36 Therapeutics is a clinical-stage biotech developing KTX-1001 (gintemetostat), a first-in-class oral, selective NSD2/MMSET inhibitor targeting epigenetic drivers of t(4;14) multiple myeloma. The company's lead program is in Phase 1 clinical development, showing target engagement and early clinical activity in relapsed/refractory patients, with a strategy of epigenetic priming to re-sensitize tumors to existing therapies and overcome adaptive resistance.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJun 2023
Dec 2021
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
